Updated from 2:13 p.m. EDT

Biotech and pharmaceutical stocks generally tracked the climbing broader market indices Thursday, but among those bucking the trend was Sanofi-Aventis ( SNY), which was still smarting from a U.S. regulatory hit the day before.

Advisers to the Food and Drug Administration recommended the agency reject Sanofi's Zimulti , which is sold in foreign markets under the name Acomplia, in part over concern that the weight-loss drug increases the risk of suicidal thinking.

Shares of France-based Sanofi closed down $1.74, or 4%, to $41.33, and that weighed on the Amex Pharmaceutical Index, of which Sanofi is a component. The index was down 0.4% at 352.07.

Getting a regulatory lift, however, was Given Imaging ( GIVN). The Israel-based gastrointestinal diagnostics company climbed 5.2% higher after receiving FDA clearance for its next-generation PillCam ESO 2 video capsule for imaging the esophagus. Exclusive U.S. marketing rights for PillCam ESO have been granted to InScope, a division of Ethicon Endo-Surgery, a Johnson & Johnson ( JNJ) company. Given Imaging was up $1.31 at $26.38.

Study news also moved stocks in the sector. Swinging more than 12% higher was DepoMed ( DEPO), which announced after Wednesday's market close that it had begun dosing patients in a phase II trial for Gabapentin GR for the treatment of menopausal hot flashes. Gabapentin GR is an extended-release formulation of gabapentin, an FDA-approved drug for the treatment of seizures and postherpetic neuralgia. DepoMed closed up 54 cents at $5.

Taking the downward tack on study results was Barrier Therapeutics ( BTRX), which announced results of a phase II/III study of a dermatology treatment that missed statistical significance for the study's primary endpoint. The pharmaceutical company said it has no plans to further develop liarozole, which was meant to treat lamellar ichthyosis, a rare genetic disorder that causes thick scaling of the skin. Shares closed down 24 cents, or 3.7%, at $6.32.

The Nasdaq Biotechnology Index, of which both DepoMed and Barrier Therapeutics are components, was up 0.6% at 823.43.

Also on the downside was QMed ( QMED), which lowered its 2007 revenue forecast to a range of $31 million to $33 million compared with the previous range of $38 million to $44.5 million. The single-analyst estimate from Thomson First Call anticipates revenue of $42.8 million. Shares of the Eatontown, N.J., health-care management systems provider were down 5 cents, or 1.6%, at $3.14.

GeoPharma ( GORX) moved higher after announcing a deal to buy EZ-Med Technologies, a company that manufactures a patented soft-textured chew technology, for an undisclosed amount. GeoPharma's shares closed up 9 cents, or 2.2%, at $4.

Among other winners Thursday were Genelabs Technologies ( GNLB), which climbed 13% after Oppenheimer initiated coverage of the biopharmaceutical company with a buy rating, and Oculus Innovative Sciences ( OCLS), which continued climbing a day after announcing a licensing deal for its first-response pen-like applicator for cuts, minor burns and skin irritations. Genelabs, of Redwood City, Calif., closed up 26 cents, at $2.26, and Petaluma, Calif.-based Oculus was up 47 cents, or 6.6%, at $7.63.